Patent FR-2834289-A1 (FR)
Title: Medicaments for inhibiting cdc25 phosphatase and/or CD 45 phosphatase, especially used for cancer treatment, comprising new or known benzoxazole- or benzothiazole-4,7-dione derivatives
Inventor: GALCERA CONTOUR MARIE ODILE
IPC: C07D417/12
Filed: 2001-12-27
Abstract: The use of amino-substituted benzoxazole- or benzothiazole-4,7-dione derivatives (I) as medicament for inhibiting cdc25 phosphatase and/or CD 45 phosphatase is new. The use of benzoxazole or benzothiazole derivatives of formula (I) or their salts is claimed in the production of a medicament for inhibiting cdc25 phosphatase and/or CD 45 phosphatase. R1 = H, alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, -CH2-X-Y', -CH2-Z-NR5R6 or -CHR35R36; or may also be carbocyclic aryl (optionally substituted (os) by 1-3 of halo, alkyl, haloalkyl or alkoxy) if W = O; R2 = H, alkyl or aralkyl; or NR1R2 = 4-8 membered heterocycle containing 1 or 2 heteroatom(s), completed by members selected from CR15R16, O, S and NR17; CHR35R36 = indanyl, tetralinyl or a 5-7 membered saturated heterocycle (containing 1 or 2 of O, N and S as heteroatoms and os on N by alkyl or benzyl); X = direct bond or 1-5C alkylene; Y' = (i) saturated carbocyclic system, comprising 1-3 fused 3-7 membered rings, (ii) a saturated heterocycle containing 1 or 2 of O, N and/or S as heteroatom(s), bonded to X via N or C and completed by 2-6 further members selected from CHR7, CO, NR8, O and S; (iii) carbocyclic or heterocyclic aryl, os by 1-3 of halo, alkyl, haloalkyl, alkoxy, haloalkoxy, OH, NO2, CN, Ph, SO2NHR9 or NR10R11; R7 = H or alkyl; R8 = H, alkyl or aralkyl; R9 = H, alkyl or Ph; R10, R11 = alkyl; Z' = direct bond or 1-5C alkylene; R5, R6 = H, alkyl, aralkyl or -(CH2)nOH; or R5 may also = alkoxycarbonyl, haloalkoxycarbonyl or aralkoxycarbonyl if R6 = H or Me; or NR5R6 = 4-7 membered heterocycle containing 1 or 2 heteroatom(s), completed by members selected from CR12R13, O, S and NR14; R12, R13 = H or alkyl; R14 = H, alkyl, aralkyl or phenyl (os by 1-3 of halo, alkyl or alkoxy); n  = 1-6; R15, R16 = H or alkyl; R17 = H, alkyl or aralkyl; R3 = H, halo, alkyl, haloalkyl, alkoxy or alkylthio; R4 = alkyl,cycloalkyl, cycloalkylalkyl, CN, NH2, CH2COOR18, CH2CONR19R20, CH2NR21R22, methylenedioxyphenyl, ethylenedioxyphenyl or carbocyclic or heterocyclic aryl (os by 1-4 of halo, alkyl, haloalkyl, alkoxy, haloalkoxy or NR37R38); R18 = H or alkyl; R19 = H, alkyl or aralkyl (os in the ring by 1-3 of halo, alkyl, haloalkyl, alkoxy, haloalkoxy, OH, NO2, CN , Ph, SO2NHR23 or NR23R24); R20 = H or alkyl; or NR19R20 = 4-7 membered heterocycle containing 1 or 2 heteroatom(s), completed by members selected from CR26R27, O, S and NR28; R23 = H, alkyl or phenyl; R24, R25 = alkyl; R26, R27 = H or alkyl; R28 = H, alkyl, aralkyl or phenyl (os by 1-3 of halo, alkyl or alkoxy); R21 = H, alkyl or aralkyl (os in the ring by 1-3 of halo, alkyl, haloalkyl, alkoxy, haloalkoxy, OH, NO2, CN, Ph, SO2NHR29 or NR30R31); R22  =  H or alkyl; or NR21R22 = 4-7 membered heterocycle containing 1 or 2 heteroatom(s), completed by members selected from CR32R33, O, S and NR34; R29 = H, alkyl or phenyl; R30, R31 = alkyl; R32, R33 = H or alkyl; R34 = H, alkyl, aralkyl or phenyl (os by 1-3 of halo, alkyl or alkoxy); R37, R38 = H or alkyl; or NR37R38 = 4-7 membered heterocycle containing 1 or 2 heteroatom(s), completed by members selected from CR39R40, O, S and NR41; R39 - R41 =  H or alkyl; and W' =  O or S. Independent claims are included for: (1) compounds (I) and their salts as medicaments, with the proviso that if W' = S and R4 = os aryl, then R1 = alkoxyalkyl, alkylthioalkyl, cycloalkyl, -CH2-X-Y' or -CH2-Z-NR5R6;  (2) pharmaceutical compositions containing compounds (I) as defined in (I), or their salts, as active agents;  (3) (I) and their salts as new compounds, with the proviso as in (i) and the additional proviso that if W' = S and R4 = alkyl, then R1 is other than H, alkyl or cycloalkyl and/or R3 = H or alkyl.